Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
This final rule is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to reschedule buprenorphine from a Schedule V narcotic to a Schedule III narcotic under the Controlled Substances Act (CSA). This action is based on a rescheduling recommendation by the Department of Health and Human Services (DHHS) and a DEA review indicating that buprenorphine meets the criteria of a Schedule III narcotic. The DEA published a proposed rule to reschedule buprenorphine on March 21, 2002 (67 FR 13114). The comment period was extended for an additional 30 days until May 22, 2002 (67 FR 20072). The DEA received ten comments but no requests for hearings. This final action will impose the regulatory controls and criminal sanctions of a Schedule III narcotic on those persons who handle buprenorphine or products containing buprenorphine
D002047:Buprenorphine / Q000145:classification* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D009270:Naloxone / Q000627:therapeutic use; D009294:Narcotics / Q000145:classification* / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D009294:Narcotics; D009270:Naloxone; D002047:Buprenorphine